Pátria exits Elfa Medicamentos, selling 99.56% control stake to Gravataí
What's the deal? Pátria InvestimentosDealroom has a profile for this one. Try Dealroom → has sold its controlling stake in Brazilian drug distributor Elfa MedicamentosDealroom has a profile for this one. Try Dealroom → to Gravataí ParticipaçõesDealroom has a profile for this one. Try Dealroom →, the company confirmed on Monday, August 24. Funds managed by Pátria offloaded 99.56% of Elfa's voting capital for R$620.49, transferring control entirely to the new owner.
How the deal is structured: Closing triggered a "liquidity event" under Elfa's bylaws, automatically converting Class A and B preferred shares into common shares. The R$620.49 purchase price was paid proportionally to the selling funds.
What changes now? Pátria's funds formally exited the control block and gave up all seats on Elfa's board. Gravataí will ask the Comissão de Valores Mobiliários (CVM) to waive a mandatory tender offer for minority shareholders, but has committed to running one if regulators reject the request.
What's the endgame? Gravataí said it takes a long-term view and will not delist Elfa within a year or pursue immediate corporate restructuring. Its focus is integrating subsidiaries, improving operational efficiency, and strengthening the company's capital structure.
What could go wrong? The contract includes an earn-out clause: Pátria's funds are entitled to an additional payment if Gravataí sells shares, stakes, or Elfa's businesses to third parties within the next 36 months.
The signal: The exit marks a clean handoff of a major Brazilian pharmaceutical distributor from a private equity manager to a buyer positioning itself for the long haul, with consolidation and integration as the stated priorities.
Read more: valor.globo.com
Image credit: Svadilfari
